ArticleHaematologica2017
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 96 citations in OpenAlex.
- Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.Leukemia · 2026Trial
- Validation and Modeling of Flow Cytometric CD36 Coefficient of Variation Analysis in the Diagnosis of Lower-Risk Myelodysplastic SyndromeTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Comment on “Validation and Modeling of Flow Cytometric CD36 Coefficient of Variation (CV) Analysis in the Diagnosis of Lower-Risk Myelodysplastic Syndromes”Turkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- [Diagnostic utility of multiparametric flow cytometric immunophenotyping in myelodysplastic neoplasms].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Translation of the Morphological Hallmarks of Dyserythropoiesis to Objective Morphometric Parameters by Imaging Flow Cytometry.International journal of laboratory hematology · 2025Article
- Article
- Evaluation of Erythroid Maturation Patterns in Unexplained anemia in the Elderly.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Single-cell data combined with phenotypes improves variant interpretation.BMC genomics · 2025Article
- 28-color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease.Cytometry. Part B, Clinical cytometry · 2025Article
- Article
- Diagnosis of myelodysplastic syndromes: the classic and the novel.Haematologica · 2025Review
- Review
- Advances in Microflow Cytometry-Based Molecular Detection Methods for Improved Future MDS Cancer Diagnosis.Current issues in molecular biology · 2024Review
- Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.Leukemia · 2024Article
- Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era.Frontiers in oncology · 2024Review
- Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes.Pathology oncology research : POR · 2024Article
- CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS.Leukemia · 2023Article
- CD36 relative mean fluorescence intensity of CD105Scientific reports · 2023Article
- Article
- Heterochromatin rewiring and domain disruption-mediated chromatin compaction during erythropoiesis.Nature structural & molecular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most flow cytometry protocols focus on the analysis of progenitor cells and the evaluation of the maturing myelomonocytic lineage. However, one of the most frequently observed features of myelodysplastic syndromes is anemia, which may be associated with dyserythropoiesis. Therefore, analysis of changes in flow cytometry features of nucleated erythroid cells may complement current flow cytometry tools. The multicenter study within the IMDSFlow Working Group, reported herein, focused on defining flow cytometry parameters that enable discrimination of dyserythropoiesis associated with myelodysplastic syndromes from non-clonal cytopenias. Data from a learning cohort were compared between myelodysplasia and controls, and results were validated in a separate cohort. The learning cohort comprised 245 myelodysplasia cases, 290 pathological, and 142 normal controls; the validation cohort comprised 129 myelodysplasia cases, 153 pathological, and 49 normal controls. Multivariate logistic regression analysis performed in the learning cohort revealed that analysis of expression of CD36 and CD71 (expressed as coefficient of variation), in combination with CD71 fluorescence intensity and the percentage of CD117
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.